It is excellent news for these patients and families. The lower...

It is excellent news for these patients and families. The lower CI 11.5 month data will shift as we have longer follow up. The issue we face is without the new care act in the USA the pathway to an NDA will require more data, ie more time and more $. They are just about out of cash, the recent flurry of 'announcements' (melanoma publication was a rehash of old info) indicates they are pumping the sp. The CEO/CFO are on crazy salaries for such a precarious finance position, and neither have shares. Not a long shot bet that they will lean heavily towards a massive dilution and cap raise rather than a deal. Will they wait for agile data, which has a 75% probability of being no better than TMZ, to raise, or go before the AGM. Some efficacy data from EVT, in place of the next to useless biomarker data they just published, would really help with either a raise or a potential deal. Please let it be a deal, even if it is $2-3 USD per NASDAQ share with trailing money off a PRV and NDA's Good luck to everyone!!!